Evommune, Inc. - 8-K Filing

Evommune reports Q3 2026 net loss of $30.9 million and announces $30 million private placement alongside EVO570 in-licensing. (Items: 2.02 Results of Operations and Financial Condition, 7.01 Regulation FD Disclosure, 9.01 Financial Statements and Exhibits)

SEC EDGAR · November 12, 2026, 21:06 UTC

Tickers: $EVMN

Read the full article at SEC EDGAR

Part of the story Evommune, Inc. - 8-K Filing (3 articles)

More Regulatory news

Stark Novus Financial Inc. - 8-K Filing SEC EDGAR · November 12, 2026, 21:44 UTC
Starling Oncology, Inc. - 8-K Filing SEC EDGAR · November 12, 2026, 21:43 UTC
Spero Therapeutics, Inc. - 8-K Filing SEC EDGAR · November 12, 2026, 21:43 UTC
BATTALION OIL CORP - 10-Q Filing SEC EDGAR · November 12, 2026, 21:43 UTC
INNOVATIVE FOOD HOLDINGS INC - 10-Q Filing SEC EDGAR · November 12, 2026, 21:42 UTC
Silexion Therapeutics Corp - 10-Q Filing SEC EDGAR · November 12, 2026, 21:42 UTC
DiaMedica Therapeutics Inc. - 10-Q Filing SEC EDGAR · November 12, 2026, 21:42 UTC
BATTALION OIL CORP - 8-K Filing SEC EDGAR · November 12, 2026, 21:41 UTC
Algorhythm Holdings, Inc. - 8-K Filing SEC EDGAR · November 12, 2026, 21:42 UTC
AMERICAN BATTERY MATERIALS, INC. - 10-Q Filing SEC EDGAR · November 12, 2026, 21:41 UTC